Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 Activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium

Foresee Pharmaceuticals announced that the company will present the clinical design of the FP-045 Phase 1/2 clinical Fanconi anemia clinical study currently being initiated, at the Fanconi Anemia...

Related Keywords

Sheraton ,British Columbia ,Canada ,Vancouver , ,Fanconi Anemia Research Fund ,Memorial Sloan Kettering Cancer Center ,Stanford University ,University Of Minnesota ,Foresee Pharmaceuticals ,Clinical Trial Evaluating ,Biological Activity ,Fanconi Anemia ,Fuschia Phase ,Sheraton Vancouver ,Grand Ballroom ,Aldehyde Dehydrogenase ,Markets ,